• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 1
      Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD - 18 hour(s) ago

      Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men’s health.

      Source: www.urologytimes.com
      Categories: General Medicine News, Urology
      Tweet Tweets with this article
      • Profile photo of 	UrologyTimes
        UrologyTimes

        🎧 New on #PearlsAndPerspectives: @AmyPearlman1 talks with men’s health expert @AlexTatem about testosterone therapy—what works, what doesn’t, and why it’s often misunderstood. From injectables to orals to estradiol, this episode has it all. 🔗 Listen: https://t.co/g5ZwKRW9sX https://t.co/0I3dX6dFkQ

    • Mashup Score: 1
      The NMIBC Treatment Landscape: Emerging Evidence and Real-World Impact - 2 day(s) ago

      Experts take a deep dive into the latest advancement, exploring groundbreaking clinical trial data, real-world evidence of newly approved therapies, and ongoing research shaping the future of NMIBC, as well as addressing the practical challenges of bringing these innovations into practice.

      Source: www.urologytimes.com
      Categories: General Medicine News, Urology
      Tweet Tweets with this article
      • Profile photo of 	UrologyTimes
        UrologyTimes

        Discover the newly approved therapies for NMIBC in the latest peer exchange, featuring expert insights and real-world evidence. Watch now: https://t.co/oTI0CyvR3S #NMIBC https://t.co/Kh46rqnR47

    • Mashup Score: 3
      SBRT may offer a safe alternative to CFRT after prostatectomy - 2 day(s) ago

      Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.

      Source: www.urologytimes.com
      Categories: General Medicine News, Urology
      Tweet Tweets with this article
      • Profile photo of 	UrologyTimes
        UrologyTimes

        "UCLA has long been a pioneer in SBRT for treating patients who have not yet had surgery, and now with the SCIMITAR trial, we have the first phase 2 data in the world to support this treatment in men who have had surgery," says @AmarUKishan. | @UclaUrology https://t.co/PaCRrR2B8M

    • Mashup Score: 5
      Laura Davis, MD, on link between microplastics and bladder cancer - 2 day(s) ago

      “The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer,” says Laura E. Davis, MD.

      Source: www.urologytimes.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	weldeiry
        weldeiry

        Laura Davis, MD, on link between microplastics and bladder cancer https://t.co/3j7UGEBQzj

    • Mashup Score: 5
      Laura Davis, MD, on link between microplastics and bladder cancer - 2 day(s) ago

      “The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer,” says Laura E. Davis, MD.

      Source: www.urologytimes.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	weldeiry
        weldeiry

        Laura Davis, MD, on link between microplastics and bladder cancer https://t.co/3j7UGEBQzj

    • Mashup Score: 1
      Administering onabotA: Improving patient comfort and easing anxiety - 3 day(s) ago

      An expert walks through specific actions that urologists and their teams can take before, during, and after the procedure.

      Source: www.urologytimes.com
      Categories: General Medicine News, Urology
      Tweet Tweets with this article
      • Profile photo of 	UrologyTimes
        UrologyTimes

        Benjamin Brucker, MD, (@PelvicMedicine) shares specific actions that physicians and other staff can take to ease patient’s anxiety and ensure comfort when administering onabotulinumtoxinA for OAB. @NYUUrology https://t.co/eV9KRAeRKi

    • Mashup Score: 9
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB - 3 day(s) ago

      Nearly 60% of patients taking vibegron remained on treatment at 1 year.

      Source: www.urologytimes.com
      Categories: General Medicine News, Urology
      Tweet Tweets with this article
      • Profile photo of 	UrologyTimes
        UrologyTimes

        Roger Dmochowski, MD, shares findings on real-world persistence with vibegron for OAB. #AUA25 @VUMCurology https://t.co/XeWV1xtWxo

    • Mashup Score: 1
      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic - 3 day(s) ago

      “The use of telemedicine is heavily dependent on supportive legislature,” write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

      Source: www.urologytimes.com
      Categories: General Medicine News, Urology
      Tweet Tweets with this article
      • Profile photo of 	UrologyTimes
        UrologyTimes

        In a recent article, Tracey Krupski, MD, (@tkrupskiuro) and Jeunice Owens-Walton, MD, (@JeuniceMED) discuss the evolution of telemedicine in urologic oncology and reflect on the legislative landscape surrounding its role in medical care. @uvaurology https://t.co/4w7jPV29yD

    • Mashup Score: 3
      Published data support safety, efficacy of vaginal insert for SUI - 4 day(s) ago

      Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.

      Source: www.urologytimes.com
      Categories: General Medicine News, Urology
      Tweet Tweets with this article
      • Profile photo of 	UrologyTimes
        UrologyTimes

        The Yōni. Fit bladder support significantly reduced pad weights and SUI events compared with a sham device, according to findings from a recently published study. #urology @JEFFObGyn https://t.co/SnsC0UOROd

    • Mashup Score: 1
      Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer - 4 day(s) ago

      ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.

      Source: www.urologytimes.com
      Categories: General Medicine News, Urology
      Tweet Tweets with this article
      • Profile photo of 	UrologyTimes
        UrologyTimes

        The 50% enrollment goal has been met in the phase 2a PROHEAR study, evaluating the safety and efficacy of ACOU085 in preventing cisplatin-induced hearing loss in patients with testicular cancer. #urology https://t.co/g23s448fqr

    Load More
    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings